Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug4001 | photobiomodulation and photodynamic therapy Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D007414 | Intestinal Neoplasms NIH | 1.00 |
D004938 | Esophageal Neoplasms NIH | 0.71 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
A multicenter Italian retrospective study on COVID-19 pandemic condition and advanced Gastro - Intestinal Cancer. Are in Italy increased the new diagnosis of GI cancer in advanced stage in the 2020 compared with 2019, as a consequence of COVID-19?
Description: The primary endpoint is to show if in Italy the number of cancer mentioned above, was diagnosed in a more advanced stage (i.e. > I stage, Metastatic disease) in 2020 compared to 2019 as a consequence of COVID-19 pandemic condition.
Measure: Rate of advanced Esophageal, Gastric, Pancreatic and Colorectal cancer in 2020 compared to 2019. Time: From January 2019 to December 2020Description: To show any difference in the rate of cancer related neo-adjuvant therapy in 2020 compared to 2019;
Measure: Rate of neo-adjuvant therapy in 2020 compared to 2019 Time: From January 2019 to December 2020Description: To show any difference in the rate of cancer related palliative procedures/ bridge therapy in 2020 compared to 2019, before starting with standard treatment;
Measure: Rate of palliative procedure in 2020 compared to 2019 Time: From January 2019 to December 2020Description: To show any difference of patients unable to performer cancer related preoperative chemo or radiotherapy in 2020 compared to 2019 due to scarce performance status or for symptomatic disease;
Measure: Rate of preoperative chemo or radiotherapy in 2020 compared to 2019 for metastatic disease. Time: From January 2019 to December 2020Description: Rate of patients unable to performer cancer related adjuvant therapy in 2020 compared to 2019 due to scarce performance status
Measure: Rate of patient unable to performer adjuvant treatment in 2020 compared to 2019 Time: From January 2019 to December 2020Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports